Shorter Peptide Nucleic Acid Probes Improve Affibody-Mediated Peptide Nucleic Acid-Based Pretargeting.
Journal
ACS pharmacology & translational science
ISSN: 2575-9108
Titre abrégé: ACS Pharmacol Transl Sci
Pays: United States
ID NLM: 101721411
Informations de publication
Date de publication:
10 May 2024
10 May 2024
Historique:
received:
28
02
2024
revised:
28
03
2024
accepted:
10
04
2024
pmc-release:
29
04
2025
medline:
16
5
2024
pubmed:
16
5
2024
entrez:
16
5
2024
Statut:
epublish
Résumé
Affibody-mediated PNA-based pretargeting shows promise for HER2-expressing tumor radiotherapy. In our recent study, a 15-mer Z
Identifiants
pubmed: 38751640
doi: 10.1021/acsptsci.4c00106
pmc: PMC11091976
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1595-1611Informations de copyright
© 2024 The Authors. Published by American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare the following competing financial interest(s): KW, AV, AO, AEK and VT own shares in Zytox Therapeutics AB. MO is employed by Affibody AB. KW, HT and AEK are co-inventors of a patent application on PNA pretargeting (PCT/EP2021/078854). The other co-authors declare no competing interest.